Gastrointestinal Cancer News

The FDA has informed Hutchmed Ltd. that the data package included in a new drug application for surufatinib to treat pancreatic and extra-pancreatic neuroendocrine tumors does not support approval in the U.S., the company announced.

Limaca Medical announced it has received breakthrough device designation from the FDA for its Precision-GI endoscopic ultrasound biopsy device, according to a company press release.

Among patients with T1 colorectal cancer, deep submucosal invasion was not a significant independent predictor for lymph node metastasis and should not be considered the sole indicator for oncologic surgery.

The U.S. Multi-Society Task Force on colorectal cancer published updated guidance for the diagnosis, assessment and management of patients with gastrointestinal hamartomatous polyposis syndromes, with a focus on cancer risk.

The addition of tislelizumab to chemotherapy significantly extended OS for patients with previously untreated advanced esophageal squamous cell carcinoma, according to a press release from the agent’s manufacturer.

Esophageal cancer is one of the deadliest forms of cancer with an estimated 19,260 diagnoses and 15,530 deaths in the United States last year, the American Association for Cancer Research reported.

Break Through Cancer will award $50 million in grants designed to maximize interdisciplinary collaboration among researchers at five top cancer centers.

The FDA granted fast track designation to CMG901 for treatment of certain patients with gastrointestinal cancers.

Patients with esophageal cancer who engaged in prehabilitation exercise demonstrated improved responses to neoadjuvant chemotherapy than those who did not, according to a study published in British Journal of Sports Medicine.

BOSTON – Christy S. Harris, PharmD, BCOP, FHOPA, discussed a presentation on the role of immunotherapy in upper gastrointestinal cancer and how it’s “trying to move the needle forward” in care.